Clinical Trial Update: A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses [Phase 2]

View source ↗

Summary

Phase 2 monocentric trial evaluating the efficacy and safety of deucravacitinib in adults with inflammatory genodermatoses; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermolysis Bullosa Simplex
• Genodermatoses
• Ichthyosis
• Inflammatory Congenital Ichthyoses

Drugs mentioned

• Deucravacitinib (deucravacitinib)

Snippet

Sponsor: Centre Hospitalier Universitaire de Nice | Conditions: Epidermolysis Bullosa Simplex, Ichthyosis | Phase 2 | Status: RECRUITING